West Pharmaceutical Services, Inc. (WST) Cut to Neutral at Bank of America Corporation

Bank of America Corporation cut shares of West Pharmaceutical Services, Inc. (NYSE:WST) from a buy rating to a neutral rating in a report published on Tuesday, October 17th, MarketBeat reports. The firm currently has $98.00 price target on the medical instruments supplier’s stock.

A number of other research analysts have also issued reports on WST. Zacks Investment Research lowered West Pharmaceutical Services from a hold rating to a sell rating in a report on Wednesday, July 19th. BidaskClub lowered West Pharmaceutical Services from a buy rating to a hold rating in a report on Wednesday, July 5th. Jefferies Group LLC raised West Pharmaceutical Services from a hold rating to a buy rating and boosted their target price for the company from $96.00 to $115.00 in a report on Friday, September 15th. Finally, Stephens began coverage on West Pharmaceutical Services in a report on Tuesday, October 3rd. They issued an equal weight rating and a $99.00 target price on the stock. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company. West Pharmaceutical Services has an average rating of Hold and an average target price of $104.00.

West Pharmaceutical Services (NYSE WST) opened at 100.93 on Tuesday. The company has a 50-day moving average of $93.83 and a 200 day moving average of $91.98. West Pharmaceutical Services has a one year low of $70.85 and a one year high of $103.36. The firm has a market cap of $7.47 billion, a P/E ratio of 43.32 and a beta of 1.12.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings data on Wednesday, October 25th. The medical instruments supplier reported $0.67 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.53 by $0.14. West Pharmaceutical Services had a return on equity of 14.02% and a net margin of 11.42%. The company had revenue of $398.20 million during the quarter, compared to analysts’ expectations of $386.02 million. During the same quarter in the previous year, the business earned $0.53 earnings per share. The firm’s revenue for the quarter was up 5.7% on a year-over-year basis. Equities research analysts expect that West Pharmaceutical Services will post $2.67 earnings per share for the current fiscal year.

WARNING: “West Pharmaceutical Services, Inc. (WST) Cut to Neutral at Bank of America Corporation” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://www.dispatchtribunal.com/2017/10/27/west-pharmaceutical-services-inc-wst-downgraded-by-bank-of-america-corporation-to-neutral.html.

A number of hedge funds have recently made changes to their positions in the stock. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its holdings in West Pharmaceutical Services by 0.3% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 10,735 shares of the medical instruments supplier’s stock worth $1,015,000 after acquiring an additional 34 shares during the period. Cambridge Investment Research Advisors Inc. grew its holdings in West Pharmaceutical Services by 1.6% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 2,569 shares of the medical instruments supplier’s stock worth $210,000 after acquiring an additional 40 shares during the period. Teacher Retirement System of Texas grew its holdings in West Pharmaceutical Services by 0.7% during the second quarter. Teacher Retirement System of Texas now owns 5,867 shares of the medical instruments supplier’s stock worth $555,000 after acquiring an additional 40 shares during the period. Hillsdale Investment Management Inc. grew its holdings in West Pharmaceutical Services by 0.7% during the second quarter. Hillsdale Investment Management Inc. now owns 12,080 shares of the medical instruments supplier’s stock worth $1,142,000 after acquiring an additional 80 shares during the period. Finally, PNC Financial Services Group Inc. grew its holdings in West Pharmaceutical Services by 2.6% during the first quarter. PNC Financial Services Group Inc. now owns 6,806 shares of the medical instruments supplier’s stock worth $556,000 after acquiring an additional 175 shares during the period. 90.17% of the stock is currently owned by hedge funds and other institutional investors.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Analyst Recommendations for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply